



Exelixis Announces August 10th Webcast of Presentation at the Canaccord Genuity Growth Conference

August 8, 2011

SOUTH SAN FRANCISCO, Calif., Aug 08, 2011 (BUSINESS WIRE) -- Exelixis, Inc. (NASDAQ:EXEL) announced today that Gisela Schwab, M.D., the company's executive vice president and chief medical officer, will present at the Canaccord Genuity Growth Conference at 3:30 p.m. EDT / 12:30 p.m. PDT on Wednesday, August 10, 2011, in Boston. During the presentation, Dr. Schwab will review the most recent publicly available data for cabozantinib in castration-resistant prostate cancer (CRPC) and discuss the pivotal trial plans and regulatory strategy for the compound in CRPC. She will also discuss the company's 2011 financial outlook and provide a general business update.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors at <http://www.exelixis.com>.

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. Exelixis is focusing its resources and development efforts exclusively on cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs. For more information, please visit the company's web site at <http://www.exelixis.com>.

SOURCE: Exelixis, Inc.

Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President
Investor Relations and Corporate Communications
cbutler@exelixis.com